The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth

Oncology Letters

Volumn 14, Issue 1, 2017, Pages 844-852

  Rodríguez Salazar, Maria Del Carmen ^a   Franco Molina, Moises Armides ^a   Mendoza Gamboa, Edgar ^a   Martínez Torres, Ana Carolina ^a   Zapata Benavides, Pablo ^a   López González, Jose Sullivan ^b   Coronado Cerda, Erika Evangelina ^a   Alcocer González, Juan Manuel ^a   Tamez Guerra, Reyes Silvestre ^a   Rodríguez Padilla, Cristina ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Damage associated molecular patterns; IMMUNEPOTENT CRP; Immunogenic cell death; Melanoma; Oxaliplatin

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL FACTOR; BIOLOGICAL PRODUCT; CALRETICULIN; CANCER ANTIBODY; DAMAGE ASSOCIATED MOLECULAR PATTERN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNEPOTENT CRP; IMMUNOMODULATING AGENT; LIPOCORTIN 5; OXALIPLATIN; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; MELANOMA; MOUSE; NONHUMAN; TUMOR VOLUME; WESTERN BLOTTING;

EID: 85020195174     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6202     Document Type: Article

References (53)

1. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L and Kroemer G: Molecular characteristics of immu-nogenic cancer cell death. Cell Death Differ 15: 3-12, 2007.
2. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L and Kroemer G: Immunogenic cancer cell death: A key-lock paradigm. Curr Opin Immunol 20: 504-511, 2008.
3. Kroemer G, Galluzzi L, Kepp O and Zitvogel L: Immunogenic cell death in cancer therapy. Annu Rev Immunol 31: 51-72, 2013.
4. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfet-tini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61, 2007.
5. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L and Kroemer G: Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14: 1848-1850, 2007.
6. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durch-schlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, et al: The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15: 1499-1509, 2008.
7. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, et al: Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28: 578-590, 2009.
8. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P and Vandenabeele P: Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12: 860-875, 2012.
9. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, Smyth MJ and Zitvogel L: Tumor Cell Death and ATP release prime dendritic cells and efficient anticancer immu-nity. Cancer Res 70: 855-858, 2010.
10. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al: Acti-vation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15: 1170-1178, 2009.
11. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al: A novel pathway combining calreticulin exposure and ATP secre-tion in immunogenic cancer cell death. EMBO J 31: 1062-1079, 2012.
12. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Séror C, Métivier D, Perfettini JL, Zitvogel L and Kroemer G: Chemotherapy induces ATP release from tumor cells. Cell Cycle 8: 3723-3728, 2009.
13. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Métivier D, Galluzzi L, Perfettini JL, et al: Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 21: 79-91, 2014.
14. Srivastava P: Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20: 395-425, 2002.
15. Srivastava P: Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2: 185-194, 2002.
16. Schmitt E, Gehrmann M, Brunet M, Multhoff G and Garrido C: Intracellular and extracellular functions of heat shock proteins: Repercussions in cancer therapy. J Leukoc Biol 81: 15-27, 2007.
17. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L and Kroemer G: Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14: 364-375, 2009.
18. Bianchi ME and Manfredi AA: High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220: 35-46, 2007.
19. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, et al: Defective immunogenic cell death of HMGB1-deficient tumors: Compensatory therapy with TLR4 agonists. Cell Death Differ 21: 69-78, 2014.
20. Fredly H, Ersvær E, Gjertsen BT and Bruserud O: Immunogenic apoptosis in human acute myeloid leukemia (AML): Primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 25: 1549-1556, 2011.
21. D'Eliseo D, Manzi L and Velotti F: Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immuno-genic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones 18: 801-808, 2013.
22. Garg AD, Krysko DV, Vandenabeele P and Agostinis P: Hypericin-based photodynamic therapy induces surface expo-sure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 61: 215-221, 2012.
23. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J and Spísek R: Human tumor cells killed by anthra-cyclines induce a tumor-specific immune response. Cancer Res 71: 4821-4833, 2011.
24. Chen HM, Wang PH, Chen SS, Wen CC, Chen YH, Yang WC and Yang NS: Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol Immunother 61: 1989-2002, 2012.
25. Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, Li J, Wang X, Gao S, Qian D, et al: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget 6: 2250-2262, 2015.
26. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et al: Cardiac glycosides exert anticancer effects by inducing immuno-genic cell death. Sci Transl Med 4: 143ra99, 2012.
27. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghir-inghelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al: Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29: 482-491, 2010.
28. Calvet CY, Famin D, André FM and Mir LM: Electro- chemotherapy with bleomycin induces hallmarks of immuno-genic cell death in murine colon cancer cells. Oncoimmunology 3: e28131, 2014.
29. Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, et al: Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 220: 22-34, 2007.
30. Dudek AM, Garg AD, Krysko DV, De Ruysscher D and Agos-tinis P: Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 24: 319-333, 2013.
31. Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O and Kroemer G: Combinatorial strategies for the induction of immunogenic cell death. Front Immunol 6: 187, 2015.
32. Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al: Molecular and translational classifications of DAMPS in immu-nogenic cell death. Front Immunol 6: 588, 2015.
33. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, et al: Trial Watch: Immunogenic cell death inducers for anticancer chemo-therapy. Onco Immunology 4: e1008866, 2015.
34. Inoue H and Tani K: Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 21: 39-49, 2014.
35. Franco-Molina MA, Mendoza-Gamboa E, Zapata-Benavides P, Vera-García ME, Castillo-Tello P, García delaFuente A, Mendoza RD, Garza RG, Támez-Guerra RS and Rodrí-guez-Padilla C: IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: A phase I study in non-small cell lung cancer patients. Cytotherapy 10: 490-496, 2008.
36. Franco-Molina MA, Mendoza-Gamboa E, Miranda- Hernández D, Zapata-Benavides P, Castillo-León L, Isaza-Brando C, Tamez-Guerra RS and Rodríguez-Padilla C: In vitro effects of bovine dialyzable leukocyte extract (bDLE) in cancer cells. Cytotherapy 8: 408-414, 2006.
37. Franco-Molina MA, Mendoza-Gamboa E, Zapata-Bena-vides P, Castillo-Tello P, Isaza-Brando CE, Zamora-Avila D, Rivera-Morales LG, Miranda-Hernández DF, Sierra-Rivera CA, Vera-García ME, et al: Antiangiogenic and antitumor effects of IMMUNEPOTENT CRP in murine melanoma. Immunophar-macol Immunotoxicol 32: 637-646, 2010.
38. Franco-Molina MA, Mendoza-Gamboa E, Castillo-León L, Tamez-Guerra RS and Rodríguez-Padilla C: Bovine dialyzable leukocyte extract modulates the nitric oxide and pro-inflam-matory cytokine production in lipopolysaccharide-stimulated murine peritoneal macrophages in vitro. J Med Food 8: 20-26, 2005.
39. Mendoza-Gamboa E, Franco-Molina MA, Zapata-Benavides P, Castillo-Tello P, Vera-García ME, Tamez-Guerra RS and Rodríguez-Padilla C: Bovine dialyzable leukocyte extract modulates AP-1 DNA-binding activity and nuclear transcription factor expression in MCF-7 breast cancer cells. Cytotherapy 10: 212-219, 2008.
40. Franco-Molina MA, Mendoza-Gamboa E, Castillo-León L, Tamez-Guerra RS and Rodríguez-Padilla C: Bovine dialyzable leukocyte extract protects against LPS-induced, murine endo-toxic shock. Int Immunopharmacol 4: 1577-1586, 2004.
41. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N and Kroemer G: Immunogenic tumor cell death for optimal anti-cancer therapy: The calreticulin exposure pathway. Clin Cancer Res 16: 3100-3104, 2010.
42. Cao C, Han Y, Ren Y and Wang Y: Mitoxantrone-mediated apop-totic B16-F1 cells induce specific anti-tumor immune response. Cell Mol Immunol 6: 469-475, 2009.
43. Tongu M, Harashima N, Yamada T, Harada T and Harada M: Immunogenic chemotherapy with cyclophosphamide and doxo-rubicin against established murine carcinoma. Cancer Immunol Immunother 59: 769-777, 2010.
44. Perez CA, Fu A, Onishko H, Hallahan DE and Geng L: Radiation induces an antitumor immune response to mouse melanoma. Int J Radiat Biol 85: 1126-1136, 2009.
45. Nowak P, Abdurahman S, Lindkvist A, Troseid M and Sönner-borg A: Impact of HMGB1/TLR ligand complexes on HIV-1 replication: Possible role for flagellin during HIV-1 infection. Int J Microbiol 2012: 263836, 2012.
46. Skitzki JJ, Repasky EA and Evans SS: Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs 10: 550-558, 2009.
47. Shi H, Cao T, Connolly JE, Monnet L, Bennett L, Chapel S, Bagnis C, Mannoni P, Davoust J, Palucka AK and Banchereau J: Hyperthermia enhances CTL cross-priming. J Immunol 176: 2134-2141, 2006.
48. Tamura Y, Peng P, Liu K, Daou M and Srivastava PK: Immu-notherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117-120, 1997.
49. Vanaja DK, Grossmann ME, Celis E and Young CY: Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells. Cancer Res 60: 4714-4718, 2000.
50. Chiang CL, Ledermann JA, Rad AN, Katz DR and Chain BM: Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. Cancer Immunol Immunother 55: 1384-1395, 2006.
51. Chiang CL, Ledermann JA, Aitkens E, Benjamin E, Katz DR and Chain BM: Oxidation of ovarian epithelial cancer cells by hypo-chlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 14: 4898-4907, 2008.
52. Chiang CL, Coukos G and Kandalaft LE: Whole tumor antigen vaccines: where are we? Vaccines (Basel) 3: 344-372, 2015.
53. Zitvogel L, Apetoch L, Ghiringhelli F and Kroemer G: Immu-nological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73, 2008.